- Conditions
- Misophonia
- Interventions
- Unified Protocol for Transdiagnostic Treatment of Emotional Disorders, Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 1,704
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Choroidal Neovascularization, Presumed Ocular Histoplasmosis
- Interventions
- EYLEA (Aflibercept) intravitreal injection
- Drug
- Lead sponsor
- Retina Research Institute, LLC
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- St Louis, Missouri
- Conditions
- Mild Traumatic Brain Injury, Concussion, Rehabilitation, Balance Impairment
- Interventions
- Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback, Vestibular therapy for mTBI
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Portland, Oregon • San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 219 participants
- U.S. locations
- 1
- States / cities
- Washington, Missouri
- Conditions
- Pregnancy, Sexually Transmitted Diseases
- Interventions
- Interactive multimedia platform, Intervention arm counseling, Standard of care counseling
- Behavioral
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 14 Years to 19 Years · Female only
- Enrollment
- 709 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Ganciclovir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 3 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Skin
- Interventions
- Blue Light Therapy
- Device
- Lead sponsor
- Efforia, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anterior Uveitis
- Interventions
- 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops
- Drug
- Lead sponsor
- Eyegate Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism, ADHD - Attention Deficit Disorder With Hyperactivity, ADHD, ASD, Alcohol Abuse/Dependence, Alcohol Addiction, Alcohol and Other Drug Use Disorders, Alcohol and Other Substance Use Prevention, Gambling Addiction, Gambling Disorder, Sex Abuse, Sex Behavior, Sex Crimes, Sex Disorder, Sex Disorders, Gender Dysphoria, Adult, Eating Behavior Disorders, Narcotic-Related Disorders, Narcotic Addiction, Narcissism, Psychiatric Disorder, Psychedelic Effects in Healthy Volunteers, Psychedelic Experiences, Psychedelic Drug Dependence, Marijuana Use Disorder, Marijuana Abuse and Dependence, Smoking (Tobacco) Addiction, Smoking Among Youth, Smoking Abstinence, Abstinence, Sex, Opiate Substitution Treatment, Opioid Abuse (Disorder), Opioid Abuse and Addiction, Cocaine Abuse, MDMA ('Ecstasy'), Addiction Disorders, Homeless and Low Incomes People, Refugees, Homelessness, Reliability and Validity, Anger Problems, Child Abuse, Sexual
- Interventions
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Behavioral
- Lead sponsor
- Veterans Recovery Network Inc.
- Other
- Eligibility
- 17 Years to 99 Years
- Enrollment
- 1,000,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2045
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- G17DT Immunogen, cisplatin, fluorouracil
- Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Obesity
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Walnut Creek, California + 15 more
- Conditions
- Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- recombinant interferon alfa
- Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2005
- U.S. locations
- 7
- States / cities
- Wichita, Kansas • New Orleans, Louisiana • Hackensack, New Jersey + 4 more
- Conditions
- Hemophilia B, Hemophilia A
- Interventions
- Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 13
- States / cities
- Palo Alto, California • San Francisco, California • Stanford, California + 7 more
- Conditions
- Stress, Stress, Psychological, Stress Physiology, Sleep, Slow Breathing
- Interventions
- Slow-Paced Breathing (SPB), Mindfulness (M), Yogic Breathing (SPB+M)
- Behavioral
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Eating Disorders, Anorexia Nervosa
- Interventions
- Open weighing, Blind weighing
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Esophagogastroduodenoscopy, Fluorouracil, Hypofractionated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Positron Emission Tomography, Survey Administration, Docetaxel, Durvalumab
- Procedure · Drug · Radiation + 2 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Durvalumab, Vicineum, Acetaminophen, Antihistamine, Bladder Biopsy, TURBT, Cystoscopy, Urine cytology, Electrocardiogram, CT, MRI
- Drug · Procedure · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cutaneous Melanoma
- Interventions
- Demographics Questionnaire, Adjuvant Treatment Beliefs Scale10, Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13, Decisional Regret14, Clinician Preference for Treatment
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Basking Ridge, New Jersey • Harrison, New York • New York, New York
- Conditions
- Dry Eye
- Interventions
- Omega 3 fatty acid, Placebos
- Drug
- Lead sponsor
- OmegaD LLC
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 14
- States / cities
- Newport Beach, California • Westminster, California • Largo, Florida + 11 more
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Ocular Brachytherapy
- Device
- Lead sponsor
- Theragenics Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 3 more
- Conditions
- Psychological Distress, Mindfulness Skills, Usability Satisfaction
- Interventions
- Mindfulness Meditation, Mindfulness Meditation with Respiration Feedback Chart and Predictive Mindfulness Skill Scores
- Behavioral
- Lead sponsor
- Equa Health
- Industry
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diabetes
- Interventions
- Tailored Patient Intervention, Patient-physician intervention, Patient and PCP intervention with analyzed data
- Device
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Dry Eye Disease
- Interventions
- 0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 23
- States / cities
- Glendale, California • Torrance, California • Colorado Springs, Colorado + 19 more
- Conditions
- Plasma Cell Leukemia
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 10
- States / cities
- New Haven, Connecticut • North Haven, Connecticut • Baton Rouge, Louisiana + 7 more